1O Integration of tissue and circulating parameters identifies a favorable immune profile in NSCLC patients treated with nivolumab.

MLA

Mazzaschi, G., et al. “1O Integration of Tissue and Circulating Parameters Identifies a Favorable Immune Profile in NSCLC Patients Treated with Nivolumab.” Journal of Thoracic Oncology, vol. 13, Apr. 2018, p. S1. EBSCOhost, https://doi.org/10.1016/S1556-0864(18)30281-8.

APA

Mazzaschi, G., Facchinetti, F., Madeddu, D., Buti, S., Gelsomino, F., Ardizzoni, A., Aversa, F., Missale, G., Quaini, F., & Tiseo, M. (2018). 1O Integration of tissue and circulating parameters identifies a favorable immune profile in NSCLC patients treated with nivolumab. Journal of Thoracic Oncology, 13, S1. https://doi.org/10.1016/S1556-0864(18)30281-8

Chicago

Mazzaschi, G., F. Facchinetti, D. Madeddu, S. Buti, F. Gelsomino, A. Ardizzoni, F. Aversa, G. Missale, F. Quaini, and M. Tiseo. 2018. “1O Integration of Tissue and Circulating Parameters Identifies a Favorable Immune Profile in NSCLC Patients Treated with Nivolumab.” Journal of Thoracic Oncology 13 (April): S1. doi:10.1016/S1556-0864(18)30281-8.